Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Clinical Features of COVID-19-Related Liver Functional Abnormality.

Tytuł:
Clinical Features of COVID-19-Related Liver Functional Abnormality.
Autorzy:
Fan Z; Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Chen L; Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Li J; Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Cheng X; Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Yang J; Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Tian C; Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Zhang Y; Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Huang S; Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Liu Z; Department of Gastroenterology, The Shanghai Tenth People's Hospital of Tongji University, Shanghai, China. Electronic address: .
Cheng J; Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Electronic address: .
Źródło:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2020 Jun; Vol. 18 (7), pp. 1561-1566. Date of Electronic Publication: 2020 Apr 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: Philadelphia, PA : W.B. Saunders for the American Gastroenterological Association, 2003-
MeSH Terms:
Liver Function Tests*
Betacoronavirus/*isolation & purification
Coronavirus Infections/*complications
Coronavirus Infections/*pathology
Liver Diseases/*epidemiology
Liver Diseases/*etiology
Pneumonia, Viral/*complications
Pneumonia, Viral/*pathology
Adult ; Antiviral Agents/therapeutic use ; Bilirubin/blood ; Blood Chemical Analysis ; COVID-19 ; China/epidemiology ; Enzymes/blood ; Female ; Hospitals ; Humans ; Liver Diseases/drug therapy ; Lopinavir/therapeutic use ; Male ; Middle Aged ; Pandemics ; Prevalence ; Retrospective Studies ; Ritonavir/therapeutic use ; SARS-CoV-2
References:
N Engl J Med. 2020 Mar 26;382(13):1199-1207. (PMID: 31995857)
Lancet Respir Med. 2020 Apr;8(4):420-422. (PMID: 32085846)
N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945)
JAMA. 2020 Mar 17;323(11):1061-1069. (PMID: 32031570)
N Engl J Med. 2003 May 15;348(20):1986-94. (PMID: 12682352)
N Engl J Med. 2020 Mar 5;382(10):929-936. (PMID: 32004427)
Virus Res. 2008 Apr;133(1):4-12. (PMID: 17825937)
Int J STD AIDS. 2019 May;30(6):620-622. (PMID: 30722751)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
Clin Infect Dis. 2005 Oct 15;41(8):1186-95. (PMID: 16163639)
Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143)
J Infect Dis. 2005 Jan 15;191(2):193-7. (PMID: 15609228)
Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507)
JAMA. 2020 Apr 14;323(14):1406-1407. (PMID: 32083643)
Am J Gastroenterol. 2005 Jan;100(1):169-76. (PMID: 15654797)
Drug Metab Rev. 2012 Feb;44(1):88-106. (PMID: 22229890)
Lancet Infect Dis. 2013 Sep;13(9):752-61. (PMID: 23891402)
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151. (PMID: 32064853)
Nat Microbiol. 2020 Apr;5(4):536-544. (PMID: 32123347)
Contributed Indexing:
Keywords: ALP; Antiviral Drug; Liver Injury; Prognosis
Substance Nomenclature:
0 (Antiviral Agents)
0 (Enzymes)
2494G1JF75 (Lopinavir)
O3J8G9O825 (Ritonavir)
RFM9X3LJ49 (Bilirubin)
Entry Date(s):
Date Created: 20200414 Date Completed: 20200602 Latest Revision: 20220603
Update Code:
20240105
PubMed Central ID:
PMC7194865
DOI:
10.1016/j.cgh.2020.04.002
PMID:
32283325
Czasopismo naukowe
Background & Aims: Some patients with SARS-CoV-2 infection have abnormal liver function. We aimed to clarify the features of COVID-19-related liver damage to provide references for clinical treatment.
Methods: We performed a retrospective, single-center study of 148 consecutive patients with confirmed COVID-19 (73 female, 75 male; mean age, 50 years) at the Shanghai Public Health Clinical Center from January 20 through January 31, 2020. Patient outcomes were followed until February 19, 2020. Patients were analyzed for clinical features, laboratory parameters (including liver function tests), medications, and length of hospital stay. Abnormal liver function was defined as increased levels of alanine and aspartate aminotransferase, gamma glutamyltransferase, alkaline phosphatase, and total bilirubin.
Results: Fifty-five patients (37.2%) had abnormal liver function at hospital admission; 14.5% of these patients had high fever (14.5%), compared with 4.3% of patients with normal liver function (P = .027). Patients with abnormal liver function were more likely to be male, and had higher levels of procalcitonin and C-reactive protein. There was no statistical difference between groups in medications taken before hospitalization; a significantly higher proportion of patients with abnormal liver function (57.8%) had received lopinavir/ritonavir after admission compared to patients with normal liver function (31.3%). Patients with abnormal liver function had longer mean hospital stays (15.09 ± 4.79 days) than patients with normal liver function (12.76 ± 4.14 days) (P = .021).
Conclusions: More than one third of patients admitted to the hospital with SARS-CoV-2 infection have abnormal liver function, and this is associated with longer hospital stay. A significantly higher proportion of patients with abnormal liver function had received lopinavir/ritonavir after admission; these drugs should be given with caution.
(Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.)
Comment in: Clin Gastroenterol Hepatol. 2020 Nov;18(12):2848. (PMID: 32371168)
Comment in: Clin Gastroenterol Hepatol. 2020 Nov;18(12):2846-2847. (PMID: 32407783)
Comment in: Clin Gastroenterol Hepatol. 2020 Sep;18(10):2384-2385. (PMID: 32425706)
Comment in: Clin Gastroenterol Hepatol. 2020 Nov;18(12):2848-2851. (PMID: 32425707)
Comment in: Clin Gastroenterol Hepatol. 2020 Oct;18(11):2633-2637. (PMID: 32553905)
Comment in: Clin Gastroenterol Hepatol. 2020 Nov;18(12):2851-2852. (PMID: 32755553)
Comment in: Clin Gastroenterol Hepatol. 2022 May;20(5):e1217-e1218. (PMID: 34311112)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies